Especially in lung cancer, various targeted therapies have been developed, ranging from EGFR-TKIs and BRAF, ALK, ROS, RET, MET, TRK1, and HER2 inhibitors [149], to more recent developments in KRAS inhibitors [150]. This evidence concerns the gene ROS1 and lung carcinoma.